Fortress Biotech Forms Subsidiary Tamid Bio to Develop Novel AAV Gene Therapies in Orphan Disease…

  • Post author:
  • Post category:BioPharma

Tamid enters exclusive licensing deal with UNC-Chapel Hill for three preclinical gene therapy product candidates.
Source: BioSpace